A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment
Conditions
- Multiple Myeloma, Refractory
- Hepatocarcinoma
- Advanced Solid Tumor
Interventions
- BIOLOGICAL: LNA-i-miR-221
Sponsor
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Collaborators